Scientists from Siberian State Medical University (SibGMU) have created a domestic equivalent of a drug for the prevention and treatment of thrombosis. This was announced by the press service of Siberian State Medical University (SibGMU).
The finished dosage form (FDF) of nadroparin calcium — a modern low-molecular-weight heparin — has already been registered in Russia. The research and production project was implemented with the support of Farmbioprom and the FMBA of Russia, with support from the Ministry of Education and Science of the Russian Federation.
The drug will be widely used in cardiology, surgery, and therapy. The medicine has passed all the necessary stages of development and has begun to be produced in Russia. Full localization of production and registration of the active substance is planned to be completed by the end of 2026, which will allow the drug to enter the market with fully domestic production.
Read more materials on the topic: